Skip to main content

Genable Receives FDA Orphan Drug Status for Ocular Disease Drug


Genable Technologies, an Irish biopharmaceutical firm, announced last week that it has received orphan drug status from the US Food and Drug Administration for its expressed RNAi-based treatment for retinitis pigmentosa.

The disease is rare degenerative eye condition that can lead to blindness. Last summer, the company took a license to Benitec Biopharma’s expressed RNAi technology for use in developing a treatment for the condition (GSN 7/19/2012).

Genable’s drug, dubbed GT038, comprises an AAV vector to deliver an shRNA that silences both the mutant and wild-type rhodopsin gene, which is mutated in retinitis pigmentosa. The company, which previously received orphan drug status for the agent from European regulators, anticipates a phase I trial of GT038 could begin in 2014.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.